Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Fatemeh
Fatemeh Ahmadnian, Berlin DE
| Patent application number | Description | Published |
|---|---|---|
| 20110224396 | PROCESS FOR PREPARING POLYETHER POLYOLS - The present invention relates to a process for the catalytic preparation of polyetherols, wherein the power input by means of at least one stirrer and/or by means of at least one pump, based on the reactor volume, is in the range from 0.001 to 8.2 kW/m | 09-15-2011 |
| 20110251345 | DEODORIZATION OF POLYMER COMPOSITIONS - The present invention relates to a method for reducing residual volatiles from polymer compositions. | 10-13-2011 |
Fatemeh Akhlaghi, Wakefield, RI US
| Patent application number | Description | Published |
|---|---|---|
| 20080255765 | MONITORING CYCLOSPORINE IN SALIVA - Saliva offers an alternative specimen for the therapeutic monitoring of cyclosporine (CsA) in children and patients with difficult venous access. For a highly protein-bound drug such as CsA, saliva provides a practical approach for measuring the unbound concentration. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is ideally suited for the measurement of drugs in saliva. A solid-phase extraction technique, analytic liquid chromatography over an Aqua Perfect column, maintained at 65° C., and electrospray tandem mass spectrometry were used to quantify CsA in saliva. The method used cyclosporine C (CsC) as the internal standard. Mobile phase comprised of a 97:3 voL mixture of methanol and 30 mmol/L ammonium acetate at a flow rate of 0.5 mL/min. Chromatograms using mass transitions of m/z 1219.9→m/z 1202.9 for CsA and m/z 1235.9→m/z 1218.9 for CsC were obtained. The calibration curve was linear from 1 to 300 μg/L with correlation coefficient values ranging from 0.9732 to 0.9968). The lower limit of quantification was 1 μg/L and limit of detection was 0.6 μg/L with an average extraction recovery of 84.7±2.6% for CsA and 93.7±4.4% for CsC from the saliva matrix. The accuracy of the method ranged from 92% to 104.7%, and the intra- and interim coefficients of variation were 6.9-12.2% and 8.3-12.1%, respectively. The correlation coefficient value between the CsA concentration measurements in 15 paired blood-saliva samples from kidney transplant recipients was 0.695 (P=0.006). The noninvasive and simple method of saliva collection coupled with the LC-MS/MS quantification technique for CsA analysis would generate novel data that could benefit patients undergoing CsA therapy. | 10-16-2008 |
| 20080318322 | ANALYSIS OF MYCOPHENOLIC ACID IN SALIVA USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY - A method for mass spectrometric analysis of a saliva sample possibly containing mycophenolic acid or its metabolites mycophenolic acid phenyl glucuronide (MPAG) or mycophenolic acid acyl-glucuronide (Acyl-MPAG), including the steps: (a) providing a saliva sample containing one or more drug or metabolites; (b) deproteinating the sample; (c) separating the one or more drug or metabolites from the saliva sample; and (d) analyzing the one or more drug or metabolites using a mass spectrometer. The sample containing one or more MPA or metabolites is obtained from in an oral fluid based biological samples i.e. whole saliva or saliva obtained by chemical or mechanical stimulation or from specific salivary glands. The size of the sample contains one or more MPA or metabolites is at least about 100 microL. A kit for use in mass spectrometric analysis of a sample may contain one or more MPA or metabolites from saliva samples, comprising: (a) reagents for deproteinating of the saliva sample, including internal standards; (b) reagents for separating the one or more MPA or metabolites from the saliva sample; (c) reagents for analyzing the one or MPA or metabolites using a mass spectrometer; (d) a solution of one or more MPA or metabolites in saliva samples; and (e) instructions for analyzing the one or more MPA or saliva using a mass spectrometer. The kit includes (a) mobile phase solutions; (b) a chromatography column; and (c) a quality control specimen. | 12-25-2008 |
| 20110281369 | ANALYSIS OF MYCOPHENOLIC ACID IN SALIVA USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY - A method for mass spectrometric analysis of a saliva sample possibly containing mycophenolic acid or its metabolites mycophenolic acid phenyl glucuronide (MPAG) or mycophenolic acid acyl-glucuronide (Acyl-MPAG), including the steps: (a) providing a saliva sample containing one or more drug or metabolites; (b) deproteinating the sample; (c) separating the one or more drug or metabolites from the saliva sample; and (d) analyzing the one or more drug or metabolites using a mass spectrometer. The sample containing one or more MPA or metabolites is obtained from in an oral fluid based biological samples i.e. whole saliva or saliva obtained by chemical or mechanical stimulation or from specific salivary glands. The size of the sample contains one or more MPA or metabolites is at least about 100 microL. A kit for use in mass spectrometric analysis of a sample may contain one or more MPA or metabolites from saliva samples, comprising: (a) reagents for deproteinating of the saliva sample, including internal standards; (b) reagents for separating the one or more MPA or metabolites from the saliva sample; (c) reagents for analyzing the one or MPA or metabolites using a mass spectrometer; (d) a solution of one or more MPA or metabolites in saliva samples; and (e) instructions for analyzing the one or more MPA or saliva using a mass spectrometer. The kit includes (a) mobile phase solutions; (b) a chromatography column; and (c) a quality control specimen. | 11-17-2011 |
Fatemeh Atyabi, Tehran IR
| Patent application number | Description | Published |
|---|---|---|
| 20100324315 | POLY(CITRIC ACID) FUNCTIONALIZED CARBON NANOTUBE DRUG DELIVERY SYSTEM - A method for synthesizing carbon nanotube drug carriers and the carbon nanotube drug carriers are disclosed. Initially, carbon nanotubes, nitric acid, and sulfuric acid are mixed to oxidize carbon nanotubes in a first mixture. The oxidized carbon nanotubes are then extracted from the first mixture. The oxidized carbon nanotubes and monohydrated citric acid are mixed to synthesize carbon nanotubes grafted with poly(citric acid) in a second mixture. The carbon nanotubes grafted with poly(citric acid) are then extracted from the second mixture. The carbon nanotubes grafted with poly(citric acid) and 4-(dimethylamino)pyridine are dissolved in anhydrous dimethylformamide in a third mixture. Next, a mixture that comprises a drug is added to the third mixture to synthesize the carbon nanotubes grafted with poly(citric acid) and the drug in a fourth mixture. Then, the carbon nanotubes grafted with poly(citric acid) and the drug are extracted from the fourth mixture. | 12-23-2010 |
Fatemeh Azmandian, Taunton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110004935 | VMM-BASED INTRUSION DETECTION SYSTEM - An intrusion detection system collects architectural level events from a Virtual Machine Monitor where the collected events represent operation of a corresponding Virtual Machine. The events are consolidated into features that are compared with features from a known normal operating system. If an amount of any differences between the collected features and the normal features exceeds a threshold value, a compromised Virtual Machine may be indicated. The comparison thresholds are determined by training on normal and abnormal systems and analyzing the collected events with machine learning algorithms to arrive at a model of normal operation. | 01-06-2011 |
Fatemeh Davami, Tehran IR
| Patent application number | Description | Published |
|---|---|---|
| 20120058537 | CHIMERIC TRUNCATED AND MUTANT VARIANT OF TISSUE PLASMINOGEN ACTIVATOR (T-PA) RESISTANT TO PLASMINOGEN ACTIVATOR INHIBITOR-1 - The various embodiments herein provide a chimeric truncated and mutant variant of a tissue plasminogen activator (t-pa) and a method for preparing the same. According to an embodiment herein, the mutant variant comprises a signal sequence domain, followed by a chimeric tetrapeptide, followed by a tripeptide, followed by a kringle 2 domain, followed by a serine protease domain and a substituted amino acids at position 128-131. The substituted amino acids are AAAA (SEQ ID NO: 3) amino acids. The chimeric tetrapeptide is Gly-His-Arg-Pro (SEQ ID NO: 1). The chimeric tetrapeptide is at a position of 36 to 39 amino acid of the mutant variant. The tripeptide is Ser-Tyr-Glu. According to an embodiment herein, a chimeric truncated and mutant variant of a tissue plasminogen activator comprises a native t-pa deleted with Finger domain, a Growth Factor domain and a Kringle 1 domain, a chimeric tetrapeptide and a substituted amino acids at a position of 128-131. | 03-08-2012 |
Fatemeh Davar, Kashan IR
| Patent application number | Description | Published |
|---|---|---|
| 20120034465 | METHOD FOR PREPARING SILICA-DYSPROSIUM OXIDE CORE-SHELL NANOPARTICLES - Silica-dysprosium oxide core-shell nanoparticles and a method for preparing the silica-dysprosium oxide core-shell nanoparticles are disclosed. Initially, ethyl silicate, n-butanol, ethylenediamine, and distilled water are mixed in the presence of ultrasonic radiation to prepare silica nanoparticles. Then, the silica nanoparticles are isolated. Next, the isolated silica nanoparticles, an acid, n-butanol, and dysprosium oxide are mixed in the presence of ultrasonic radiation to prepare silica-dysprosium oxide core-shell nanoparticles. Finally, the silica-dysprosium oxide core-shell nanoparticles are isolated. | 02-09-2012 |
Fatemeh Hajibagher, Debrecen HU
| Patent application number | Description | Published |
|---|---|---|
| 20110180672 | Airplane with aerodynamic stall-prevention layout and pertinent longitudinal stability arrangement - General purpose airplane with a swept back wing provided with a sharp leading edge as to cause flow separation and stall of the wing in cases where the limits of the regular flight envelope are exceeded in terms of angle of attack, and as a result to cause the front part of the airplane to move downward, said airplane also having positive lift-producing horizontal stabilizer provided with rounded leading edge, which does not stall at this point, therefore holds the tail in level during the process, all together acting to restore the original flight attitude. The horizontal stabilizer is essentially a straight (or similar) wing with a steeper lift-coefficient curve as that of the swept-back wing, therefore, in case of an un-commanded pitch-up of the airplane the greater increase of lift on the horizontal stabilizer together with its greater moment arm provides the stabilizing force to counter such pitching. | 07-28-2011 |
Fatemeh Maleky, Kitchener CA
| Patent application number | Description | Published |
|---|---|---|
| 20100143644 | APPARATUS AND METHOD FOR SOLIDIFYING A MATERIAL UNDER CONTINUOUS LAMINAR SHEAR TO FORM AN ORIENTED FILM - A method of solidifying a fluid comprising a material into an oriented film. The method includes pumping the fluid into a channel at an input end thereof at a predetermined pressure sufficient to push the material to an output end of the channel. The channel is at least partially defined by a substantially smooth outer surface of an inner tube and a substantially smooth inner surface of an outer tube. The method also includes subjecting the material to laminar shear at a predetermined rate by rotating one of the inner tube and the outer tube relative to the other. The predetermined rate is selected to promote solidification of the fluid into the oriented film. Also, the method includes cooling the material at a predetermined rate as the material moves through the channel from the input end to the output end to promote solidification of the fluid into the oriented film. | 06-10-2010 |
Fatemeh Mojtabai, Demarest, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110218120 | ORDERED TWO- AND THREE-DIMENSIONAL STRUCTURES OF AMPHIPHILIC MOLECULES - The invention pertains, at least in part, to a method for forming an ordered structure of amphiphilic molecules, such as proteins. The method includes contacting a population of amphiphilic molecules with a interface; compressing said population laterally to an appropriate pressure, such that an ordered structure at the interface is formed. The invention also pertains to the two- and three-dimensional ordered structures that are formed using the planar membrane compression method of the invention. | 09-08-2011 |
Fatemeh Mojtabai, Lexington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080219592 | Self-similar ordered microstructural arrays of amphiphilic molecules - The invention pertains, at least in part, to a method for determining the structure of an amphiphilic molecule using Self-Similar Microstructure Arrays. | 09-11-2008 |